CBC

2024 Canadian Screen Award Winners Announced

Retrieved on: 
Samstag, Juni 1, 2024
Devery, Cinespace Film Studios, Gordon Sinclair Award, Spin Master, Comedy, CBC, Pop icon, Telefilm Canada, News, Canada Media Fund, The Hardy Boys, Hope, Creativity, CBC Television, Magic, CTV, Television, Crave, Insight Productions, Drag race, Screen Awards, Earle Grey Award, Screen, Canadian Broadcasting Centre, Screenplay, Motion, Drop, MADE, Science, Film industry

TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- The Academy of Canadian Cinema & Television celebrated the final award show of Canadian Screen Week 2024 tonight at the CBC Broadcast Centre in Toronto, marking the end of four days that celebrated the achievements of Canadian talent in film, television, and digital media.

Key Points: 
  • "To our dedicated team who brought Canadian Screen Week to life, and the visionary winners of the 2024 Canadian Screen Awards, your commitment to excellence is not only recognized but celebrated as the cornerstone of our industry's success.
  • The 2024 Canadian Screen Awards, which just aired on CBC and CBC Gem, invited viewers into The 2024 Canadian Screen Awards Gala that took place earlier this evening.
  • Canadian Screen Week 2024 comes to a close on Saturday, June 1, 2024 with the Board Tribute Dinner, the Canadian Academy’s annual fundraising event, supported by Patron Partners Bell Media and Cineplex.
  • The event will honour the esteemed 2024 Special Award recipients, where this year’s Industry Leadership Award honouree, Michael MacMillan, will be presented with his award.

The Leukemia & Lymphoma Society and Tasso Announce Partnership to Advance Blood Cancer Research

Retrieved on: 
Donnerstag, Mai 30, 2024
Oncology, Health, Other Science, General Health, Clinical Trials, Research, Science, Partnership, Patient, Bone marrow, LLS, Clinical trial, Leukemia & Lymphoma Society, Doctor of Philosophy, Travel, Lymphoma, Immunodeficiency, CBC, Beat, Leukemia, Complete blood count, Entrepreneurship

The Leukemia & Lymphoma Society® (LLS), a global leader in the fight against blood cancer, and Tasso, Inc. , the leading provider of patient-centric, clinical grade blood collection solutions, today announced a collaboration to accelerate blood cancer research.

Key Points: 
  • The Leukemia & Lymphoma Society® (LLS), a global leader in the fight against blood cancer, and Tasso, Inc. , the leading provider of patient-centric, clinical grade blood collection solutions, today announced a collaboration to accelerate blood cancer research.
  • Frequent clinic visits and venipuncture blood draws are a burden on patients with leukemia, lymphoma, and other blood cell disorders.
  • To reduce the burden on blood cancer patients, LLS and Tasso are collaborating on a clinical trial evaluating a new patient-centric strategy for collecting critical Complete Blood Count (CBC) using the Tasso device in blood cancer patients with low blood counts.
  • “As a true patient-centric organization, The Leukemia & Lymphoma Society seeks out innovations that can make receiving care easier for blood cancer patients,” said Ashley Yocum, Ph.D., Executive Research Strategy Lead of the Beat AML® Master Clinical Trial at LLS.

Belgium Cards and Payments Industry Report 2024: Market Trends, Opportunities and Risks 2019-2023 & 2024-2028 - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Mai 28, 2024
Professional Services, Payments, Technology, Finance, Fintech, Banking, Health, ING, KBC, Wero, Amazon Prime, Food, Klarna, Debit Mastercard, CBC, Research, POS, Amazon, Beobank, Banque Nagelmackers, Banco Santander, Bank

The "Belgium Cards and Payments Market, Opportunities and Risks to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Belgium Cards and Payments Market, Opportunities and Risks to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The report provides detailed analysis of market trends in the Belgian cards and payments industry.
  • To aid the development of digital payments, the European Payments Initiative (EPI) announced the launch of its mobile wallet solution Wero, in September 2023.
  • Current and forecast values for each market in the Belgian' cards and payments industry, including debit, credit and charge cards.

Former U.S. HUD Secretary and Presidential Cabinet Member Marcia L. Fudge Joins Taft

Retrieved on: 
Montag, Mai 13, 2024
Theta, HUD, COVID-19, African, University, Delta Sigma, Housing, CBC, Partner, Congressional Black Caucus, Public policy, Culture, Cuyahoga County, Ohio, Delta Sigma Theta, Ohio State University, Multimedia, African Americans

Former Secretary Fudge is the second African American woman to lead HUD, having steered the agency through a housing crisis exacerbated by the COVID-19 pandemic.

Key Points: 
  • Former Secretary Fudge is the second African American woman to lead HUD, having steered the agency through a housing crisis exacerbated by the COVID-19 pandemic.
  • Former Secretary Fudge will dedicate a portion of her time to the firm's ongoing efforts to combat the harmful effects of forever chemicals.
  • From 2008 until 2021, former Secretary Fudge served as the U.S. Representative for the 11th Congressional District of Ohio.
  • Former Secretary Fudge will also play an important role in recruiting additional top legal talent to Taft.

My Friend Omar: the Battle of a Seasonal Worker is now available on CBC Gem

Retrieved on: 
Montag, Mai 13, 2024
ICI, Seasonworker, Deportation, Canadian Broadcasting Corporation, Workforce, Guatemalan, CBC Television, CBC, Christian de la Cortina, Social isolation, Environment, Violence

A new documentary sheds light on the vulnerability of temporary foreign workers under closed work permits in Canada.

Key Points: 
  • A new documentary sheds light on the vulnerability of temporary foreign workers under closed work permits in Canada.
  • The documentary My Friend Omar: the Battle of a Seasonal Worker traces the tortuous journey and abuses endured by Wilson Omar Mendez, a Guatemalan seasonal worker working on a Quebec farm.
  • The documentary My Friend Omar: The Battle of a Seasonal Worker is now available for broadcast on the online listening platforms CBC Gem and ICI Tou.TV.
  • It will also be broadcast several times on Radio-Canada and CBC over the coming weeks.

RSA Conference Closes Out 33rd Annual Event by Discovering the Art of What's Possible Together

Retrieved on: 
Freitag, Mai 10, 2024
Privacy, SANS Institute, Amazon Web Services, SAN, Mathematical sciences, United States Navy, Harvard University, Senior, CBC, Homeland security, Architecture, SentinelOne, Public policy, Conference, Ethics, Community engagement, Field, Security, AI safety, Award, Justice minister, Partner, ICSF, Security engineering, Student, RSA Conference, RET, Safety, Policy, SANS, Moscone Center, Faculty, Organization, ESAF, CLF, Stanford University, Government, Pulse, Artificial intelligence, AI, Mathematics, State, RSA, Knowledge, Ultimate, Transformation, Medical device

SAN FRANCISCO, May 10, 2024 /PRNewswire/ -- RSA Conference™, the world's leading cybersecurity conferences and expositions, today concluded its 33rd annual event at the Moscone Center in San Francisco.

Key Points: 
  • SAN FRANCISCO, May 10, 2024 /PRNewswire/ -- RSA Conference™, the world's leading cybersecurity conferences and expositions, today concluded its 33rd annual event at the Moscone Center in San Francisco.
  • "It's been so exciting as always, to watch our community convene in San Francisco for RSA Conference and this year was no exception," said Linda Gray Martin, Senior Vice President, RSA Conference.
  • RSA Conference 2024 by the Numbers:
    41,000+ attendees, including 650 speakers across 425 sessions, 400+ media members, and 600 exhibitors on the expo floors.
  • RSA Conference 2024 highlights include:
    Reality Defender named "RSA Conference 2024's Most Innovative Startup" by the Innovation Sandbox's judges' panel comprised of technology, venture, and security industry thought leaders.

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024

Retrieved on: 
Freitag, Mai 10, 2024
Inflammation, RNA, UC, Hepatology, Patient, Northwestern University, CBC, Associate, Division

Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY

Key Points: 
  • Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2
    Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
    Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Abivax has also sponsored a Product Theater presentation titled, “ An Investigational New MOA that Can Stabilize the Inflammatory Response in Ulcerative Colitis ,” taking place on May 20, 2024, at 2:30-3:15 p.m. EDT in room “DDW Theater 1,” featuring Prof. Parambir S. Dulai, M.D., Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois, U.S.

Cronos Group Reports 2024 First Quarter Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Cream, Mazor Robotics, Genetics, Certified Public Accountant, Wedding cake, Investment, Fully Charged, Average cost, Capital, EY, Pharma, Depreciation, Cannabinol, Flower, Robotics, Traction, GMO, Partnership, Research, Capital expenditure, Medtronic, Tax, Senior, Patient, Vii, Hamas, CBC, Motus, CBN, Lord, CBG, Growth, Drug

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2024 first quarter business results.

Key Points: 
  • Cronos Growing Company Inc. ("Cronos GrowCo") reported to the Company preliminary unaudited net revenue to licensed producers, excluding sales to the Company, of approximately $5.1 million in the first quarter of 2024.
  • Cronos previously provided Cronos GrowCo with a senior secured credit facility, which currently has approximately $67.1 million outstanding following a principal repayment of $1.2 million by Cronos GrowCo in Q1 2024.
  • In addition to principal repayment, Cronos also received $1.4 million in interest payments from Cronos GrowCo, totaling approximately $2.7 million in cash payments to Cronos in Q1 2024.
  • Before becoming Head of Cronos Israel, he was the Vice President of Finance at Cronos Israel managing the Cronos Israel finance department.

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024

Retrieved on: 
Mittwoch, Mai 8, 2024
Inflammation, RNA, UC, Hepatology, Patient, Northwestern University, CBC, Associate, Division

Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY

Key Points: 
  • Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2
    Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
    Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Abivax has also sponsored a Product Theater presentation titled, “ An Investigational New MOA that Can Stabilize the Inflammatory Response in Ulcerative Colitis ,” taking place on May 20, 2024, at 2:30-3:15 p.m. EDT in room “DDW Theater 1,” featuring Prof. Parambir S. Dulai, M.D., Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois, U.S.

Beckman Coulter and MeMed Extend Partnership Advancing Host Immune Response Diagnostics

Retrieved on: 
Dienstag, Mai 7, 2024
Ambiguity, BV, Genetically modified bacteria, TRAIL, Risk, Infection, Procalcitonin, Sepsis, CRP, Septic shock, Partnership, Research, NPV, PCT, Patient, Microbiology, Physician, Ministry, Serum, MDW, Beckman Coulter, CBC, Risk assessment, Viral, US FDA, Vaccine

BREA, Calif. and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed BV® assay, a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key®, a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe. This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers.

Key Points: 
  • BREA, Calif. and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership.
  • Beckman Coulter is now an authorized distributor of the MeMed BV® assay , a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key® , a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe.
  • This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers .
  • "To that end, we are excited to extend our partnership with MeMed by expanding market access to the MeMed Key and BV assay.